Search Results
Your search for ,ShE matches 5598 pages
Showing 3701 - 3750Five-Year Survival Quadrupled in Responders to Immunotherapy for Non–Small Cell Lung Cancer
At 5 years, the overall survival rate was 16% in patients with advanced non–small cell lung cancer (NSCLC) treated with single-agent nivolumab (Opdivo), according to follow-up of a phase Ib dose-ranging study (CA209-003), presented at the American Association for Cancer Research (AACR) Annual...
Nivolumab/Ipilimumab Combination Improves Survival Over Ipilimumab Alone in Patients With Melanoma
The race is on to identify combinations of immune checkpoint inhibitors that can improve outcomes over the use of immune checkpoint inhibitor monotherapy. Updated results of the phase III CheckMate 067 trial found the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) improved survival in...
ELCC 2017: Some Patients With Lung Cancer Benefit From Immunotherapy Even After Disease Progression
Some patients with advanced lung cancer benefit from immunotherapy, even after the disease has progressed as evaluated by standard criteria, according to research presented by Artal-Cortes et al at the 2017 European Lung Cancer Conference (ELCC, Abstract 96PD). The findings pave the way for certain ...
ELCC 2017: Osimertinib Improves Symptoms in Advanced Lung Cancer
Osimertinib (Tagrisso) improved cancer-related symptoms in patients with advanced lung cancer, according to an analysis of patient-reported outcomes from the AURA3 phase III clinical trial presented by Lee et al at the 2017 European Lung Cancer Conference (ELCC, Abstract 85O). “With my...
CDK4/6 Inhibitors: Their Role in Breast Cancer
The robust progression-free survival benefits achieved with the use of the CDK4/6 inhibitors palbociclib or ribociclib in the metastatic setting provided the impetus to study these agents in early-stage breast cancer. Adjuvant studies are underway, but they take time to mature. For evaluating...
ELCC 2017: Men May Need More Frequent Lung Cancer Screening Than Women
Men may need more frequent lung cancer screening than women, according to research to be presented by Koo et al at the 2017 European Lung Cancer Conference (ELCC). The U.S. Preventive Services Task Force recommends annual screening for lung cancer with low-dose computed tomography (CT) in adults...
Second Cancers May Be Deadlier in Pediatric, Adolescent, and Young Adult Patients
Second cancers in children as well as adolescents and young adults (AYAs) are far deadlier than they are in older adults and may partially account for the relatively poor outcomes of cancer patients aged 15 to 39 years overall, according to a new study by University of California (UC), Davis...
Low Cervical Cancer Screening Rates Found Among Women With Severe Mental Illness
Women enrolled in California's Medicaid program (Medi-Cal) who have been diagnosed with severe mental illness have been screened for cervical cancer at much lower rates than other women, according to a new study by researchers at the University of California, San Francisco (UCSF), published by...
Expect Questions About Continued Risk of Melanoma
Survivors of melanoma are more likely to limit their exposure to ultraviolet radiation than those who have not had the disease, but more than 10% continue to intentionally tan, according to a study published in Cancer Epidemiology, Biomarkers and Prevention.1 The study surveyed 724 people diagnosed ...
Some Melanoma Survivors Continue to Seek Sun Exposure, Risking Second, Potentially More Serious Melanoma
Long-term survivors of melanoma are more likely than those who have not been diagnosed with the disease to use sunscreen, protective clothing, and other means to limit exposure to the sun, according to a survey of melanoma survivors and controls about ultraviolet radiation exposure and protective...
Better Vision Function May Be Related to Better Quality of Life in Patients With Head and Neck Cancer
Better vision function seems to be related to better quality of life after treatment for head and neck cancer, particularly among patients who have had surgery, according to Hsiao-Lan Wang, PhD, RN, Assistant Professor in the College of Nursing at the University of South Florida. Head and neck...
Fear Has Become a Big Part of My Survivorship
Just 32 when I first felt a lump in the top of my left breast, I never expected it to be cancer or my life would irrevocably change in that instant. With no history of breast cancer in my family, I initially shook off any thoughts that I could have a serious disease and instead consoled myself...
Expert Point of View: Susan O'Brien, MD
Susan O’Brien, MD, Associate Director for Clinical Science, Chao Family Comprehensive Cancer Center, University of California Irvine Health, put the venetoclax (Venclexta) monotherapy study in context. “The study by Jones et al is impressive. Patients who fail on a prior kinase...
Updated Data on Treatment With Ibrutinib and Venetoclax in Patients With CLL/SLL
Long-term follow-up of treatment with ibrutinib (Imbruvica) in patients with previously untreated and treated chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) has shown high response rates that are durable. At 5 years, 89% of patients with treatment-naive and relapsed or...
Study Projects HIV-Related Cancer Burden to Decline
The total number of cancer cases diagnosed among people living with the human immunodeficiency virus (HIV) is projected to decline in coming years, due mostly to declines in non-Hodgkin lymphoma and Kaposi sarcoma. Certain other cancers, such as prostate and lung, are expected to rise, according to ...
Treatment of Diffuse Large B-Cell Lymphoma Continues to Evolve
Although the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) has improved with R-CHOP—the addition of rituximab (Rituxan) to the cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy regimen—one-third of patients still relapse after therapy, and patients with the ...
Judy E. Garber, MD, MPH, Receives AACR Joseph H. Burchenal Memorial Award
Judy E. Garber, MD, MPH, Director of the Center for Cancer Genetics and Prevention at Dana-Farber Cancer Institute, has been honored by the American Association for Cancer Research (AACR) for outstanding achievement in clinical cancer research. Dr. Garber, a medical oncologist and clinical cancer...
NCCN Foundation Board of Directors Names New Leadership
The NCCN Foundation® has named Gena Cook, Cofounder and Chief Executive Officer of Navigating Cancer, as Chair of the National Comprehensive Cancer Network® (NCCN®) Foundation Board of Directors. Ms. Cook, who was elected to the Board in 2010, succeeds Ellen O. Tauscher, former U.S....
Stage I Lung Cancer: Treatment Advances Have Changed the Game
Read more in the Journal of Oncology Practice (JOP). Visit ASCOPubs.org/journal/jop Patients with stage I lung cancer are achieving excellent local tumor control, thanks to an evolution in radiotherapy and surgical approaches. Jeffrey A. Bogart, MD, Professor and Chair of the Department of...
Ophira Ginsburg, MD, to Lead New High Risk Program at NYU Langone’s Perlmutter Cancer Center
Medical oncologist Ophira Ginsburg, MD, has joined New York University (NYU) Langone’s Perlmutter Cancer Center as Director of its new High Risk Program, which identifies, studies, and cares for patients with hereditary syndromes that increase cancer risk. Dr. Ginsburg also holds a faculty...
Expert Point of Review: Amrita Krishnan, MD
Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research at the City of Hope in Duarte, California, told The ASCO Post that the most exciting drug in the “New Agents” session she moderated at the 2016 American Society of Hematology (ASH) Annual Meeting...
FNIH Awards Lurie Prize in Biomedical Sciences to David M. Sabatini, MD, PhD
The Foundation for the National Institutes of Health (FNIH) has selected David M. Sabatini, MD, PhD, to receive its 5th annual Lurie Prize in Biomedical Sciences for discovery of the mTOR (mechanistic target of rapamycin) cellular pathway as a key regulator of growth and metabolism in response to...
ASCO Selects 2017–2018 Health Policy Fellows
ASCO has announced that Alexander Chin, MD, MBA, and Joanna C. Yang, MD, have been selected for the 2017–2018 ASCO Health Policy Fellowship program, now entering its second year. The fellowship, aimed at early career oncologists, provides the skills necessary to monitor and shape the regulatory and ...
Cranberry
Scientific Name: Vaccinium macrocarpon Common Names: Mossberry, sassamanash, bounceberry Case Study M.C. is a 55-year-old woman with a history of stage I endometrial cancer, diagnosed and curatively treated 5 years ago. Since then, she has been having urinary tract infections from time to time....
Paula H. Finestone, PhD, Joins Fox Chase Cancer Center
Fox Chase Cancer Center has announced the hiring of Paula H. Finestone, PhD, a psychologist who has joined the Center’s Department of Medicine. Before arriving at Fox Chase, Dr. Finestone was a clinical psychologist at Bryn Mawr Rehab, where she worked with inpatients and outpatients facing...
Kristy L. Weber, MD, Named Second Vice President, AAOS Board of Directors
Orthopedic surgeon Kristy L. Weber, MD, became the second Vice President of the American Academy of Orthopaedic Surgeons (AAOS) Board of Directors at the organization’s 2017 Annual Meeting. Her new role is the first position in a 4-year term of volunteer service that includes Dr. Weber serving as...
Progress in Defining Molecular Signature for Aggressive Androgen-Indifferent Prostate Cancer
Prostate cancer has lagged behind breast cancer in the identification of predictive and prognostic biomarkers, but the field is catching up. Researchers have identified a molecular signature that can distinguish aggressive prostate cancer that is androgen-indifferent and will have a better response ...
Joanne Berger-Sweeney, PhD, MPH, Elected to Cold Spring Harbor Laboratory Board of Trustees
Cold Spring Harbor Laboratory has announced the election of Joanne Berger-Sweeney, PhD, MPH, President of Trinity College, to its Board of Trustees. “We are pleased to welcome Dr. Berger-Sweeney to the board of Cold Spring Harbor Laboratory. Her leadership at premier academic institutions in the...
Onset of Diabetes or Its Rapid Deterioration Can Be an Early Warning Sign of Pancreatic Cancer
The onset of diabetes, or a rapid deterioration in existing diabetes that requires more aggressive treatment, could be a sign of early, hidden pancreatic cancer, according to research presented by Autier et al at the 2017 European Cancer Congress (Abstract 540).1 Study Design and Key Findings...
ASCO Honors Researchers, Scientists for Significant Advances in Cancer Treatment and Care
ASCO and the Conquer Cancer Foundation (CCF) proudly announce the winners of ASCO’s Special Awards, the Society’s highest honors, and the CCF Women Who Conquer Cancer Mentorship Award. The recipients of these awards include researchers, patient advocates, and global oncology leaders who have worked ...
Can You Hear Me Now? Listening to the Cancer Patient
At this year’s ASCO Quality Care Symposium, Neeraj K. Arora, PhD, Associate Director at the Patient-Centered Outcomes Research Institute, opened his presentation by stressing that integrating the patient’s voice and experience into the clinical setting produces better health outcomes.1 Dr. Arora,...
Decision Aid Improves Breast Cancer Patients’ Knowledge of Surgical Options
A Web-based decision aid that allows women with early breast cancer to easily compare surgical treatment options helps them make more informed decisions, suggests a randomized trial reported at the 2017 Society of Surgical Oncology (SSO) Annual Cancer Symposium.1 “Having knowledge of surgical...
Expert Point of View: Suzanne L. Topalian, MD
“Avelumab (Bavencio) is the very first drug approved for Merkel cell carcinoma, an orphan disease that is uncommon in the United States. For that reason, pharmacologic development has been slow. In this case, laboratory evidence provided a rationale for testing checkpoint inhibitors in Merkel cell ...
Attrition High but Positive Trends Observed in Web-Based Intervention Addressing Caregiver Burden
High attrition but positive trends such as increased “benefit finding” were observed with a Web-based intervention designed to address the psychosocial burden on informal caregivers, according to Allison J. Applebaum, PhD, a licensed clinical psychologist at Memorial Sloan Kettering Cancer Center...
AACR Introduces New Incoming Officers of the Associate Member Council
The American Association for Cancer Research (AACR) issued congratulations to Allison S. Betof, MD, PhD, on her election to Chairperson-elect of the Associate Member Council (AMC) of AACR. Dr. Betof assumed office at the AACR Annual Meeting earlier this month and will serve as Chairperson-elect...
Dual HER2 Targeting of HER2-Positive Metastatic Colorectal Cancer Shows Clinical Benefit
The combination of trastuzumab (Herceptin) plus lapatinib (Tykerb) achieved positive results in patients with heavily pretreated, HER2-positive metastatic colorectal cancer, according to the final results of the phase II HERACLES-A trial. This two-pronged, HER2-directed approach achieved clinical...
Thomas E. Starzl, MD, PhD, ‘Father of Modern Transplantation,’ Dies at Age 90
Scientific and clinical pioneers have one thing in common: they move beyond their comfort zone and take calculated risks. One such pioneer, whose calculated risks gave hope to otherwise hopelessly ill people, was Thomas E. Starzl, MD, PhD, who performed the world’s first successful liver...
Forging a New Role to Make Curing More Cancers a Reality
For more than 3 decades, Nancy E. Davidson, MD, has dedicated her clinical and research career to better understanding the molecular mechanisms driving the development of breast cancer and to the discovery of more effective therapies to treat the disease. The recipient of an ASCO Young...
Practice-Changing Research: Making Palliative Care a Routine Part of Cancer Care in the United States and Abroad
With its recently issued clinical practice guideline update, reviewed in this issue of The ASCO Post, ASCO has spoken: Interdisciplinary palliative care teams improve the outcomes of cancer care; patients live longer and feel better.1 There is no doubt. Multiple well-designed studies show the...
Fred Hutchinson’s Paulovich Laboratory to Lead Protein Assay Work for National Cancer Moonshot
The Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) network, which represents a partnership among the National Cancer Institute (NCI), the Department of Defense, and the Department of Veterans Affairs, has tapped the Paulovich Laboratory at Fred Hutchinson Cancer Research...
Expert Point of View: Al Covens, MD
Al Covens, MD, Professor and Chair of Gynecologic Oncology at the University of Toronto, and Head of Gynecologic Oncology at Sunnybrook Health Science Centre, commented on the phase II findings of axalimogene filolisbac: “As almost all cervical cancers are human papillomavirus (HPV)-related, this...
Lauren Lawrence, MBA, RHIA, Appointed Vice President of Karmanos Cancer Network
Lauren Lawrence, MBA, RHIA, has been promoted to Vice President of Karmanos Cancer Network. She will report to Justin Klamerus, MD, MMM, President of Karmanos Cancer Hospital and Karmanos Cancer Network. Ms. Lawrence most recently served as Executive Director of Community-Based Programs at the...
Elizabeth M. Jaffee, MD, Named AACR President-Elect 2017–2018
Elizabeth M. Jaffee, MD, was elected by the members of the American Association for Cancer Research (AACR) as its President-Elect for 2017–2018. She officially became President-Elect at the AACR Annual Meeting 2017, held in Washington, April 1–5, and will assume the presidency in April 2018 at the ...
Young Women With Metastatic Breast Cancer: Unique Needs and Concerns
Patients with breast cancer who perceive having enough and the right kinds of social support tend to be less stressed, although a paucity of research exists on the social support needs of young women with metastatic breast cancer, according to Amanda Ginter, PhD. Dr. Ginter, Assistant Professor in ...
Harnessing Implementation Science to Improve Cancer Care Delivery
Implementation science encompasses the study of methods to accelerate integration of evidence into practice and policy to improve health-care outcomes. At the 2017 ASCO Quality Care Symposium, Sandra A. Mitchell, PhD, CRNP, of the Division of Cancer Control and Population Sciences at the National...
‘Non-Engineered’ T-Cell Therapy Produces Durable Responses in Hematologic Malignancies
Adoptive T-cell therapy using “non-engineered” T cells has been showing activity in hematologic malignancies, according to a presentation by Ann M. Leen, PhD, at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium.1 Dr. Leen is an immunologist and works at the Center for Cell and Gene Therapy,...
The Mystery of Grace
The day after I told Nell she had seven metastases to her brain, she sent me flowers. She was my patient; I was her oncologist. I had met her 1 year prior, when she was well into her cancer journey, stage IV breast cancer at diagnosis. I took over from her current oncologist, who was moving. At...
ASCO’s State of Cancer Care in America: 2017 Report Acknowledges Both the Progress Made in Oncology Care and the Challenges Ahead
Despite advances in cancer risk assessment, prevention, disease detection, drug development, and health-care delivery, which have led to unparalleled reductions in cancer incidence and mortality, access to affordable health care and increased administrative burdens placed on oncology practices...
Expert Point of View: Eloise Chapman-Davis, MD
Eloise Chapman-Davis, MD, a gynecologic oncologist at New York-Presbyterian and Weill Cornell Medicine, commented on the SOLO2 trial results for The ASCO Post. “SOLO2 is the third randomized trial to evaluate the use of maintenance therapy in a selected subgroup of ovarian cancer patients with...
AACR 2017: 5-Year Survival Rate for Nivolumab-Treated Advanced Lung Cancer Higher Than Historical Rate in Early-Phase Trial
Treatment with the immune checkpoint inhibitor nivolumab (Opdivo) yielded durable responses in some patients with advanced non–small cell lung cancer (NSCLC), with a 5-year survival rate of 16%, according to data from a phase I clinical trial presented by Brahmer et al at the American...
